AEON Biopharma, Inc. financial data

Symbol
AEON on NYSE
Location
5 Park Plaza, Suite 1750, Irvine, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 78.7 % +161%
Debt-to-equity -149 % -42.6%
Return On Equity -58.6 %
Return On Assets -0.03 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.8M shares -70.4%
Common Stock, Shares, Outstanding 11.6M shares -70.6%
Entity Public Float 17M USD +19.7%
Common Stock, Value, Issued 9K USD +125%
Weighted Average Number of Shares Outstanding, Basic 11.6M shares +2019%
Weighted Average Number of Shares Outstanding, Diluted 11.6M shares +2019%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.52M USD -38.6%
Operating Income (Loss) -9.62M USD +37.9%
Nonoperating Income (Expense) 9.61M USD +5.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3K USD +26.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -3K USD +26.5%
Earnings Per Share, Basic 14 USD/shares +96.5%
Earnings Per Share, Diluted 9 USD/shares +96.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.93M USD +1004%
Assets, Current 7.41M USD +213%
Property, Plant and Equipment, Net 181K USD -29.8%
Operating Lease, Right-of-Use Asset 1.11M USD -17.4%
Other Assets, Noncurrent 29K USD 0%
Assets 8.73M USD +118%
Accounts Payable, Current 2.53M USD -45.5%
Employee-related Liabilities, Current 1.55M USD -1.02%
Liabilities, Current 8.23M USD -23.3%
Operating Lease, Liability, Noncurrent 957K USD -20.5%
Liabilities 28.6M USD -20.7%
Retained Earnings (Accumulated Deficit) -434M USD 0%
Stockholders' Equity Attributable to Parent -19.9M USD +38.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -28.6M USD +81.3%
Liabilities and Equity 8.73M USD +118%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.91M USD +8.04%
Net Cash Provided by (Used in) Financing Activities 18.3M USD +267%
Net Cash Provided by (Used in) Investing Activities 260M USD
Common Stock, Shares Authorized 1.04B shares +108%
Common Stock, Shares, Issued 11.6M shares -70.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.4M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.93M USD +1004%
Deferred Tax Assets, Valuation Allowance 59.6M USD +10.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 61M USD +12.7%
Operating Lease, Liability 1.2M USD -9.61%
Payments to Acquire Property, Plant, and Equipment 4K USD
Lessee, Operating Lease, Liability, to be Paid 1.32M USD -12.1%
Property, Plant and Equipment, Gross 506K USD +0.8%
Operating Lease, Liability, Current 247K USD +93%
Lessee, Operating Lease, Liability, to be Paid, Year Two 307K USD +3.37%
Lessee, Operating Lease, Liability, to be Paid, Year One 297K USD +69.7%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 119K USD -31.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 318K USD +3.58%
Deferred Tax Assets, Operating Loss Carryforwards 36M USD +25.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 16.1M USD +9.85%
Lessee, Operating Lease, Liability, to be Paid, Year Four 329K USD +3.46%
Operating Lease, Payments 72K USD -10%
Additional Paid in Capital 414M USD +3.04%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 19K USD -24%
Deferred Tax Assets, Net of Valuation Allowance 1.43M USD +831%
Share-based Payment Arrangement, Expense 1M USD -37.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%